MOR-202 (Daratumumab biosimilar)
Multiple Myeloma
Clinical DevelopmentIn Development
Key Facts
Indication
Multiple Myeloma
Phase
Clinical Development
Status
In Development
Company
About Mochida Pharmaceutical
Founded in 1895, Mochida Pharmaceutical is a long-standing Japanese pharmaceutical company focused on the research, development, and commercialization of innovative medicines and healthcare products. The company operates across three core segments: Prescription Pharmaceuticals, Consumer Healthcare (OTC), and Diagnostics. Its strategy combines the lifecycle management of its established revenue-generating products with targeted R&D in areas such as oncology, immunology, and rare diseases to drive future growth.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |